-
If you actually looked at these papers, it would be clear as day that they have nothing to do with unhealthy levels.
-
Aromatase gene mutation… an exception, yes. I’ve seen one case in tens of thousands of cases. I’ll bet you the keys to my Lincoln Navigator that nobody in this forum has that gene mutation.
-
Please demonstrate, using your own evidence (which you still have not provided) what level of estradiol is harmful.
-
You’re asking me to post evidence. I’ve sent you a shit ton of papers and you haven’t provided diddley squat. Perhaps you can provide something in return first because, for the umpteenth time, you haven’t provided anything.
-
I can’t discount your studies yet as you haven’t sent me any studies. Again and again. Not sure how many times I have to say you haven’t provided me anything.
-
You’re asking me to provide something that supports my position, and, again, I’ve provided a ton of papers demonstrating benefits of estradiol and why it should never be blocked. You have provided nothing yet you want me to provide more evidence?
Can you be more stupid? I don’t think you can. I believe you have reached your genetic potential in this department.
Even if you decided to ignore all the literature, which I know you did, and just skip to the conlusion of the first paper, you would have read the following:
Recent evidence has demonstrated that many biological actions historically attributed to testosterone are instead, at least in part, mediated by its aromatization product E2. The data are strongest for effects on bone, fat mass, insulin resistance and VMS. The relevance of these
data is that clinically efficacious treatment of male hypogonadism is best achieved with testosterone, which provides ‘three hormones in one’ – testosterone, DHT, E2. Conversely, this evidence raises caution regarding the use of selective androgen receptor modulators, nonaromatizable androgens and AIs for male hypogonadism, and emphasizes the need for better understanding of the tissue-specific effects of SERMs, which are also used off label by some practitioners for this purpose. They also suggest that E2, either as sole ADT or as add-back to conventional GnRH analog-based ADT, may be a promising treatment to mitigate some of the adverse effects of ADT given to men with prostate cancer.
Where do they say that there was a limit in serum levels where managing it with an anti-cancer medication designed for women was required? They didn’t. Why? Because there was no evidence of that being the case. Just like there was no evidence that estradiol causes you to grow a third testicle, or a second head, or a tail. If they saw estradiol doing anything, they would have listed it, because they listed all their findings in great detail.
Either provide some god damn evidence or stop commenting. You’re the epitome of a forum troll right now.